Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2

NCT04561063 is registered in ClinicalTrials.gov with University of Witwatersrand, South Africa as lead sponsor.

NCT NCT04561063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04561063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
Lead sponsor
University of Witwatersrand, South Africa
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2020
Completion date
February 28, 2022
Enrollment
1,950 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov infection